{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-037559","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.338804+00:00","generated_at":"2026-06-06T01:31:25.309093+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NewAmsterdam Pharma prices $175.3M public offering of shares and pre-funded warrants","bullets":["Priced 4,488,159 ordinary shares at $19.00/share and 4,736,841 pre-funded warrants at $18.9999 each.","Gross proceeds of approximately $175.3 million before underwriting discounts and expenses.","Underwriters granted 30-day option for up to 1,383,750 additional shares, exercised in full.","Net proceeds expected to be approximately $188.8 million including option exercise.","Offering closed on February 16, 2024; Jefferies, Leerink, Piper Sandler, RBC Capital Markets as joint book-runners."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-037559","json":"https://secwatch.observer/filing/0001193125-24-037559.json","markdown":"https://secwatch.observer/filing/0001193125-24-037559.md","text":"https://secwatch.observer/filing/0001193125-24-037559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524037559/0001193125-24-037559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524037559/d790577d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:31:25.309093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5b590f5a47e5f58131718217da880750ebf55bc","claim":"NewAmsterdam Pharma Co N.V. entered into Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Piper Sandler & Co. and RBC Capital Markets, LLC, as representatives of the several underwriters valued at $188.8 million (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Piper Sandler & Co. and RBC Capital Markets, LLC, as representatives of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 4,488,159 of the Company’s ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $19.00 per share","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524037559/0001193125-24-037559-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC, Leerink Partners LLC, Piper Sandler & Co. and RBC Capital Markets, LLC, as representatives of the several underwriters"},{"label":"Value","value":"$188.8 million"},{"label":"Effective","value":"2024-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}